A recent example is the androgen receptor (AR)-PROTACGT20029 (undisclosed structure), which entered Phase I clinical trialin China for androgenetic alopecia and acne.46 However, when systemic administration is required, targeted deliverysystems may overcome limitations of poor selectivity and invivo pharmacokinetic (PK) profiles. Here, AR is linked to androgenetic alopecia.